Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Shlaes

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
ACS Infectious Diseases|May 12, 2021
Innovation, Nontraditional Antibacterial Drugs, and Clinical UtilityDavid M Shlaes
Current Opinion in Pharmacology|October 16, 2003
The abandonment of antibacterials: why and wherefore?David M Shlaes
Current Opinion in Investigational Drugs (London, England : 2000)|February 28, 2006
An update on tetracyclinesDavid M Shlaes
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 16, 2020
Can Europe Pull It Together?David M Shlaes
ACS Infectious Diseases|June 13, 2020
Antibacterial Drugs: The Last FrontierDavid M Shlaes
ACS Infectious Diseases|June 13, 2020
Personal View of the Antibiotic Value PropositionDavid M Shlaes
ACS Infectious Diseases|September 14, 2016
Research and Development of Antibiotics: The Next BattlegroundDavid M Shlaes
Antimicrobial Agents and Chemotherapy|October 30, 2019
The Economic Conundrum for Antibacterial DrugsDavid M Shlaes
Annals of the New York Academy of Sciences|January 26, 2013
New β-lactam-β-lactamase inhibitor combinations in clinical developmentDavid M Shlaes
Antimicrobial Agents and Chemotherapy|May 29, 2014
Eight more ways to deal with antibiotic resistanceMatthew Metz, David M Shlaes
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
ACS Infectious Diseases|May 12, 2021
Innovation, Nontraditional Antibacterial Drugs, and Clinical UtilityDavid M Shlaes
Current Opinion in Pharmacology|October 16, 2003
The abandonment of antibacterials: why and wherefore?David M Shlaes
Current Opinion in Investigational Drugs (London, England : 2000)|February 28, 2006
An update on tetracyclinesDavid M Shlaes
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 16, 2020
Can Europe Pull It Together?David M Shlaes
ACS Infectious Diseases|June 13, 2020
Antibacterial Drugs: The Last FrontierDavid M Shlaes
ACS Infectious Diseases|June 13, 2020
Personal View of the Antibiotic Value PropositionDavid M Shlaes
ACS Infectious Diseases|September 14, 2016
Research and Development of Antibiotics: The Next BattlegroundDavid M Shlaes
Antimicrobial Agents and Chemotherapy|October 30, 2019
The Economic Conundrum for Antibacterial DrugsDavid M Shlaes
Annals of the New York Academy of Sciences|January 26, 2013
New β-lactam-β-lactamase inhibitor combinations in clinical developmentDavid M Shlaes
Antimicrobial Agents and Chemotherapy|May 29, 2014
Eight more ways to deal with antibiotic resistanceMatthew Metz, David M Shlaes
Pageof 3